Skip to main content
Top
Published in: Infection 4/2015

01-08-2015 | Original Paper

Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany

Authors: Barbara N. Gross, Michaela Steib-Bauert, Winfried V. Kern, Holger Knoth, Johannes P. Borde, Sabine Krebs, Martin J. Hug, Ulrich Rothe, Ludwig Maier, Katja de With

Published in: Infection | Issue 4/2015

Login to get access

Abstract

Background

The consumption of antifungal agents increased over the last decade, resulting in the development of resistant organisms and causing a significant pharmaco economic burden. Antifungal drugs are widely used for the treatment of systemic fungal infections and high-risk patients, especially with severe hematological or oncological conditions. Up to date, there are no reliable and systematically reported data on the consumption of antifungal substances on a nationwide level available. The presented study gives an update to the previously published multicenter study investigating antifungal consumption in different settings from five university hospital centers in Germany from 2001 to 2003.

Methods

Consumption data for systemic antifungal drugs were obtained through the hospital pharmacies for 2001–2003 and 2008–2011 regarding the medical and surgical services of five university hospital centers in Germany (A-E). Drug use densities were calculated as yearly RDDs/100 patient days. These calculations were performed for the surgical and medical services, and independently for surgical and medical ICUs, as well as for the hematology–oncology services.

Results

We report an increased utilization of systemic antifungal drugs in both study periods. The mean drug use density (mean value of all 5 hospitals) in the medical services increased by 24 % between 2001 and 2003. In 2011, this value was 37 % above the level from 2001 (12.4 RDD/100 patient days in 2001, 15.4 RDD/100 patient days in 2003, 17.0 RDD/100 patient days in 2011). The 4-year average drug use density (2008–2011) of medical services ranged between 11.6 RDD/100 patient days (hospital E) and 23.8 RDD/100 patient days (hospital A). Drug use densities were in medical intensive care units 29.4 RDD/100 patient days and hematology–oncology services 49.9 RDD/100 patient days.

Conclusions

Despite the variability of the prescribing patterns between the tertiary hospitals, the presented pharmaco-epidemiological data are a cornerstone for the initiation and implementation of effective antifungal stewardship programmes and might serve as important benchmarking information for other hospitals with similar structures and baseline settings.
Literature
1.
2.
go back to reference Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–8.PubMedCrossRef Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–8.PubMedCrossRef
3.
go back to reference Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect. 2012;18:E389–95.PubMedCrossRef Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect. 2012;18:E389–95.PubMedCrossRef
4.
go back to reference Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother. 2011;66:2880–6.PubMedCrossRef Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother. 2011;66:2880–6.PubMedCrossRef
5.
go back to reference Kim SH, Shin JH, Kim E-C, Lee K, Kim M-N, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol. 2009;47:296–304.PubMedCrossRef Kim SH, Shin JH, Kim E-C, Lee K, Kim M-N, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol. 2009;47:296–304.PubMedCrossRef
6.
go back to reference Lai C-C, Chu C-C, Wang C-Y, Tsai H-Y, Cheng A, Lee Y-C, et al. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents. 2012;40:349–53.PubMedCrossRef Lai C-C, Chu C-C, Wang C-Y, Tsai H-Y, Cheng A, Lee Y-C, et al. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents. 2012;40:349–53.PubMedCrossRef
7.
go back to reference Olaechea-Astigarraga PM, Alvarez-Lerma F, Palomar-Martínez M, Insausti-Ordeñana J, López-Pueyo MJ, Seijas-Betolaza I, et al. Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006–2010. Enferm Infect Microbiol Clin. 2012;30:435–40.CrossRef Olaechea-Astigarraga PM, Alvarez-Lerma F, Palomar-Martínez M, Insausti-Ordeñana J, López-Pueyo MJ, Seijas-Betolaza I, et al. Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006–2010. Enferm Infect Microbiol Clin. 2012;30:435–40.CrossRef
8.
go back to reference Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef
9.
go back to reference Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef
10.
go back to reference Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRef Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRef
11.
go back to reference Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect. 2012;18:1–8.PubMedCrossRef Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect. 2012;18:1–8.PubMedCrossRef
12.
go back to reference Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18:9–18.PubMedCrossRef Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18:9–18.PubMedCrossRef
13.
go back to reference Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.PubMedCrossRef Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.PubMedCrossRef
14.
go back to reference Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18:38–52.PubMedCrossRef Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18:38–52.PubMedCrossRef
15.
go back to reference Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect. 2012;18:68–77.PubMedCrossRef Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect. 2012;18:68–77.PubMedCrossRef
16.
go back to reference Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20:76–98.PubMedCrossRef Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20:76–98.PubMedCrossRef
17.
go back to reference Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–15.PubMedCrossRef Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–15.PubMedCrossRef
18.
go back to reference Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010;10:150.PubMedCentralPubMedCrossRef Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010;10:150.PubMedCentralPubMedCrossRef
19.
go back to reference Nivoix Y, Launoy A, Lutun P, Moulin J-C, Phai Pang K-A, Fornecker L-M, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506–13.PubMedCrossRef Nivoix Y, Launoy A, Lutun P, Moulin J-C, Phai Pang K-A, Fornecker L-M, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506–13.PubMedCrossRef
20.
go back to reference Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33:338–45.PubMedCrossRef Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33:338–45.PubMedCrossRef
21.
go back to reference López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56–61.PubMedCrossRef López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56–61.PubMedCrossRef
22.
go back to reference Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55:418–24.PubMedCrossRef Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55:418–24.PubMedCrossRef
Metadata
Title
Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany
Authors
Barbara N. Gross
Michaela Steib-Bauert
Winfried V. Kern
Holger Knoth
Johannes P. Borde
Sabine Krebs
Martin J. Hug
Ulrich Rothe
Ludwig Maier
Katja de With
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0742-5

Other articles of this Issue 4/2015

Infection 4/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.